Biotech industry magazine Endpoints cited William Blair’s Biopharma Rx quarterly report in its summary of activity for the sector and its investors in third quarter 2024.
“Nine months into the year, biotech is on track to surpass the total amount of private financing from 2023,” the firm wrote in a report that was cited by the publication.